| SOXS 1.79 4.07% | NVDA 177.19 -4.16% | ONMD 1.02 44.60% | NFLX 96.24 13.77% | JEM 0.096 3.90% | ENSC 0.6232 57.77% | BYND 0.9456 15.32% | PLUG 1.79 -6.28% | SOFI 17.76 -7.02% | NVD 7.53 8.50% | TZA 6.23 5.06% | NU 14.98 -0.53% | DUST 3.54 -3.50% | BITO 9.06 -2.78% | EOSE 5.695 -15.50% | XLF 51.43 -2.04% | BAC 49.83 -4.72% | AAL 13.07 -6.24% | MARA 8.94 5.80% | VEEA 0.5071 17.33% | SPY 685.99 -0.48% | SOXL 62.77 -3.93% | SLV 84.99 5.64% | XWEL 1.49 9.56% | QQQ 607.29 -0.32% | ONDS 10.08 -3.54% | BHAT 0.0495 -11.13% | PSKY 13.51 20.84% | INTC 45.61 0.33% | F 14.095 -2.19% | AAPL 264.18 -3.21% | XLE 55.92 1.58% | TQQQ 49.52 -1.06% | TSLA 402.51 -1.49% | HYG 80.72 -0.16% | TSDD 9.18 2.91% | TSLL 14.7 -3.10% | BATL 5.52 33.01% | RKT 18.19 2.36% | RXT 1.95 -14.47% | TLT 90.82 0.61% | TSLS 5.64 1.62% | WBD 28.17 -2.19% | PATH 10.73 0.14% | CRWV 79.56 -18.51% | IBIT 37.19 -2.80% | LQD 111.68 -0.04% | SOUN 8.6015 -4.21% | PLTR 137.19 0.92% | CPNG 19.08 1.98%

Boston Scientific Corporation (NYSE: BSX) Sees Positive Outlook from Citigroup Upgrade

Boston Scientific Corporation (NYSE:BSX) is a leading player in the medical device industry, known for its innovative solutions in various healthcare segments. The company focuses on developing and manufacturing medical devices used in interventional medical specialties, including cardiology, urology, and neurology. Boston Scientific competes with other major medical device companies like Medtronic and Abbott Laboratories.

On January 14, 2026, Citigroup upgraded its rating for Boston Scientific to a "Buy" recommendation, with the stock priced at $94.14. This upgrade comes as Boston Scientific continues to make strategic moves to enhance its market position. The company's participation in the 44th Annual J.P. Morgan Healthcare Conference provided a platform to showcase its future plans and innovations, potentially influencing investor sentiment and impacting stock prices.

Boston Scientific is experiencing an expansion in its profit margins, driven by the growth of its electrophysiology and WATCHMAN franchises. This shift towards higher-margin products is improving earnings quality and supporting growth in the MedTech sector. As hospitals increase capital expenditures and procedural growth normalizes, the favorable product mix shift is enhancing earnings quality, allowing for margin expansion and increased cash flow stability.

The company recently announced a definitive agreement to acquire Valencia Technologies Corporation, aiming to expand its urology offerings. Valencia Technologies is known for its innovative solutions in treating bladder dysfunction, including the eCoin System. This acquisition is expected to enhance Boston Scientific's capabilities in addressing overactive bladder issues, impacting nearly 30 million adults in the U.S.

Currently, BSX is priced at $94.14, reflecting a decrease of 1.65% or $1.58. The stock has fluctuated between $92.69 and $95.45 during the trading day. Over the past year, BSX has reached a high of $109.50 and a low of $85.98. With a market capitalization of approximately $139.6 billion, today's trading volume for BSX stands at 9,689,369 shares.

Published on: January 14, 2026